ULUdom LikhitwonnawutVideoHIVAsia-Pacific HIV Prevention Meeting 2022Pro Standpoint of the Debate - Udom LikhitwonnawutView Video
JBJakkrapatara BoonruangMDVideoHIVAsia-Pacific HIV Prevention Meeting 2022Pro Standpoint of the Debate | Jakkrapatara Boonruang, MDView Video
GEGGlenda E. GrayMBBCH, FCPaeds (SA), DScVideoHIVAsia-Pacific HIV Prevention Meeting 2022Update on HIV Vaccine and Monoclonal Antibody | Glenda E. Gray, MBBCH, FCPaeds (SA), DScView Video
RSRobin SchaeferBA, MPH, PhDVideoHIVAsia-Pacific HIV Prevention Meeting 2022Long-Acting PrEP in Low- And Middle-Income Countries - Robin Schaefer, BA, MPH, PhDView Video
JFJulie FoxMBChB. BSc. MRCP. MDVideoHIVAsia-Pacific HIV Prevention Meeting 2022PEP in the Era of PrEP - Julie Fox, MBChB. BSc. MRCP. MDView Video
SlidesetHIVAsia-Pacific HIV Prevention Meeting 2022CON Perspective - Debate: When Available, Long-Acting Cabotegravir Should be the First Option for PrEP in Public Health Setting - Viet (Mason) TrinhView Slideset
GEGGlenda E. GrayMBBCH, FCPaeds (SA), DScSlidesetHIVAsia-Pacific HIV Prevention Meeting 2022Update on HIV Vaccine and Monoclonal AntibodyView Slideset
RSRobin SchaeferBA, MPH, PhDSlidesetHIVAsia-Pacific HIV Prevention Meeting 2022Long-Acting PrEP in Low- And Middle-Income CountriesView Slideset
AAAlejandro AfaniMDSlidesetHIVMexican HIV Clinical Forum 2022Initial Therapy. Two or Three Drugs - Alejandro AfaniView Slideset
NFNicole FinkelsteinSlidesetHIVMexican HIV Clinical Forum 2022PrEP - The Mexican Experience - Nicole FinkelsteinView Slideset
LAQLuis Adrián QuirozSlidesetHIVMexican HIV Clinical Forum 2022Client Experience With Therapeutic HIV Prevention Options - Luis Adrián QuirozView Slideset
ALIAlvaro López IñiguezMDSlidesetHIVMexican HIV Clinical Forum 2022Mexican Treatment Guidelines - Similarities and Differences - Alvaro López IñiguezView Slideset
